50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Disordered Gene Expression in Hematologic Malignancy, Including Epigenetic Regulation (II)

Monday, December 8, 2008: 3:30 PM-5:30 PM

Golden Gate Hall (San Francisco Marriott)

Moderators:

María-Eugenia Figueroa and Lucio H. Castilla, PhD

3:30 PM

593

Evi1 Promotes Leukemogenesis by Anti-Apoptotic Rather Than Differentiation-Blocking Effects in Murine MLL-AF9 Leukemia

Ashish Kumar, MBBS, PhD, Quanzhi Li, PhD^*, Wendy A Hudson^*, Thien N Sam^*, Weili Chen^* and John H Kersey, MD^*

Masonic Cancer Center, University of Minnesota, Minneapolis, MN

3:45 PM

594

Genetics and Epigenetics of the PU.1 Upstream Regulatory Element: AML1 Binding Sites Are Critical for Leuekmia Induced by the AML/ETO9a Fusion Oncogene

Pu Zhang, MD¹, Gang Huang²^*, Alex Ebralidze¹^*, Jun-Yan Zhang¹^*, Annalisa DiRuscio¹^*, Chris Hetherington¹^*, Elena Levantini¹^* and Daniel G. Tenen¹^*

¹Harvard Medical School, Harvard Institutes of Medicine, Harvard Stem Cell Institute, Boston, MA
²Hema. & Onco., Memorial Sloan-Kettering Cancer Center, New York, NY

4:00 PM

595

Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes

Li Zhou¹^*, Joanna B. Opalinska¹, Davendra P. Sohal¹^*, Yongkai Mo¹, Suman Kambhampati²^*, Simrit Parmar³^*, Christina Alencar¹^*, Christoph Heuck¹^*, Ivette Vigoda¹^*, Chun Ng¹^*, Perry Pahanish¹^*, Swati Goel¹^*, Carolina Schinke¹^*, Lawrence Cytryn⁴, Ellen Friedman⁴^*, Maria E Figueroa⁵, Amittha Wickrema, PhD⁶, John Greally¹^* and Amit Verma¹

¹Albert Einstein College of Medicine, Bronx, NY
²Veterans Affairs, Kansas University Medical Center, Kansas City, MO
³UT Southwestern, Dallas
⁴Montefiore Med. Center, Bronx, NY
⁵Weill Cornell Medical College, New York, NY
⁶University of Chicago, Chicago, IL

4:15 PM

596

Specific Promoter CpG Island Methylation Patterns Identify Different Subgroups of MLL - Rearranged Infant Acute Lymphoblastic Leukemia, and Define Clinical Outcome

Dominique JPM Stumpel, MD¹^*, Pauline Schneider¹^*, Eddy HJ van Roon, MSc²^*, Judith M Boer, PhD²^*, Renee X Menezes, PhD¹^*, Rob Pieters, MD, PhD³ and Ronald W. Stam, Ph.D.¹^*

¹Dept. of Pediatric Onc./Hem., Erasmus Medical Center, Rotterdam, Netherlands
²Leiden Genome Technology Center and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands, Leiden
³Dept. of Pediatric Hem./Onc., Erasmus Medical Center, Rotterdam, Netherlands

4:30 PM

597

Comprehensive Genomic and DNA Methylation Analysis in Twins with ETV6-RUNX1 Acute Lymphoblastic Leukemia

Manoo Bhakta, MD¹^*, Mathias Ehrich, MD²^*, Eric J. Gratias, MD¹, James R. Downing, MD³^* and Charles G Mullighan, MBBS(Hons), MSc, MD⁴

¹University of Tennessee at Chattanooga and T.C. Thompson Children's Hospital, Chattanooga, TN
²Sequenom, Inc., San Diego, CA
³Administration, St. Jude Children's Research Hospital, Memphis, TN
⁴Pathology, St. Jude Children's Research Hospital, Memphis, TN

4:45 PM

598

Microrna 124 and Its Role in Response to Epigenetic Therapy in Patients with Acute Mylogenous Leukemia and Myelodysplastic Syndrome

Ryan J Castoro^*, Mhair Dekmezian^*, Amanda J Saraf^*, Yoshiyuki Watanabe^*, Woonbok Chung^*, Samih El Adhab^*, Jaroslav Jelinek^* and Jean-Pierre Issa, MD

Dept. of Leukemia, University of Texas, Houston, TX

5:00 PM

599

Differences Between Normal and Leukemic Stem Cell-Specific Methylome Indicates Aberrantly Silenced Genes Involved in the Pathogenesis of Malignant Evolution

Rebecca D Ganetzky, B.A.¹^*, Ying Jiang, M.D., Ph.D.²^*, Jeffrey Falk, Ph.D.³^*, Mingjie Jin, Ph.D.³^*, Dongyan Liu, M.S.³^*, Soledad Negrotto, Ph.D.⁴^*, Yogen Saunthararajah, M.D.⁴ and Jaroslaw P. Maciejewski, MD, PhD⁴

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH
²Hematologic Oncology and Blood Disorders/Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³Aviva Systems Biology, San Diego, CA
⁴Experimental Hematology and Hematopoiesis, Cleveland Clinic Foundation, Cleveland, OH

5:15 PM

600

Epigenetic Manipulation of Cancer Testis Antigen (CTA) Expression: A Strategy for Manipulating the Graft-Versus Leukaemia Response in Patients Allografted for Haematological Malignancies

Tatjana Stankovic, MD., PhD¹^*, Andrew McLarnon¹^*, Angelo Agathanggelou¹^*, Oliver Goodyear¹^*, Charles Craddock²^* and Paul Moss, MBBS, PhD, FRCP¹

¹CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom
²Centre for Clinical Haematology, University Hospital Birmingam, Birmingham, United Kingdom

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

602.O2.8 Disordered Gene Expression in Hematologic Malignancy, Including Epigenetic Regulation (II)